Video

Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.

While overall deemed to be well-tolerated, the most common side effects that were experienced by patients were nausea, vomiting, fatigue, and anemia. These side effects get significantly better over the course of treatment.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of thumbnail.
Image of doctor.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Image of woman.
Image of smiling doctor.
Related Content